Literature DB >> 15082234

Adenoviral gene transfer of aspartoacylase ameliorates tonic convulsions of spontaneously epileptic rats.

Takahiro Seki1, Hiroaki Matsubayashi, Taku Amano, Kazuhiro Kitada, Tadao Serikawa, Masashi Sasa, Norio Sakai.   

Abstract

The spontaneously epileptic rat (SER: tm/tm, zi/zi) shows both absence-like seizures and tonic convulsions. Our previous studies have demonstrated that absence-like seizures of the tremor rat (tm/tm), one of the parent strains of SER, were inhibited by adenoviral transfer of the aspartoacylase (ASPA) gene, a deleted gene in the tremor rat. In the present study, we examined whether the adenoviral gene transfer of ASPA inhibited the tonic convulsions of SER. Replication-defective recombinant adenoviral vectors carrying the rat ASPA gene (AxASPA) or Escherichia coli beta-galactosidase gene (AxLacZ), as a control, were constructed. After it was confirmed that AxASPA-infected HeLa cells expressed ASPA in vitro, AxASPA or AxLacZ was administered into the left lateral ventricle of 11-week-old SER. The occurrence and duration of tonic convulsions in SER were evaluated before and after the administration of adenoviral vector. Intracerebroventricular administration of AxASPA (5 x 10(7) plaque forming units) transiently, but significantly, inhibited the occurrence of tonic convulsions in SER without affecting the duration per single convulsion 7 days after the administration. No inhibitory effects were observed 10 and 14 days after AxASPA administration. In contrast, the administration of AxLacZ did not have any effect on tonic convulsions in SER. Survival rates did not differ between AxASPA- and AxLacZ-treated SERs. Adenoviral gene transfer of ASPA, one of the deleted genes of SER, transiently rescued SERs from tonic convulsion, although it did not improve their survival time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082234     DOI: 10.1016/j.neuint.2003.10.009

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  5 in total

Review 1.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

2.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 3.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

Review 4.  Advances on genetic rat models of epilepsy.

Authors:  Tadao Serikawa; Tomoji Mashimo; Takashi Kuramoro; Birger Voigt; Yukihiro Ohno; Masashi Sasa
Journal:  Exp Anim       Date:  2014-10-14

5.  Abnormal alterations in the Ca²⁺/CaV1.2/calmodulin/caMKII signaling pathway in a tremor rat model and in cultured hippocampal neurons exposed to Mg²⁺-free solution.

Authors:  Xintong Lv; Feng Guo; Xiaoxue Xu; Zaixing Chen; Xuefei Sun; Dongyu Min; Yonggang Cao; Xianbao Shi; Lei Wang; Tianbao Chen; Chris Shaw; Huiling Gao; Liying Hao; Jiqun Cai
Journal:  Mol Med Rep       Date:  2015-08-18       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.